Infinimmune, a biotechnology company pioneering antibody discovery and design, today announced the appointment of Srikanth Pendyala, M.D., as Chief Medical Officer. In this role, Dr. Pendyala will lead clinical and regulatory strategy across Infinimmune’s pipeline, including first-in-human trials of IFX-101 and IFX-201.

https://www.businesswire.com/news/home/20260513738533/en/Infinimmune-Appoints-Srikanth-Pendyala-M.D.-as-Chief-Medical-Officer